Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market - GBI Research Reports

Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market

Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market - GBI Research Reports
Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market
Published Sep 30, 2010
101 pages — Published Sep 30, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research's pharmaceuticals report, 'Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market', provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market. The report analyzes the markets for hepatitis therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the global hepatitis therapeutics market is one of the growing markets of the pharmaceutical business. Due to the approval of potential new drugs as well as combinational therapies, the hepatitis market will grow further. Launch of drugs with significant efficacy, safety and resistance profiles will fuel rapid uptake of drugs in near future. The limitations of current standard care therapy for hepatitis due to high incidence of adverse events, long duration of treatment, suboptimal patient compliance, lack of efficacy in specific genotypes has increased interest in developing novel products that can probably counter the unmet needs presented by the present market. However, the market sales growth is expected to slow down marginally due to the declining hepatitis incidence rates (use of vaccines), public awareness, and patent expiries of key therapeutics. Nevertheless, the global hepatitis market is still forecasted to grow at a compound annual growth rate (CAGR) of 3.1% between 2001 and 2009.

Scope

- Annualized market data for the hepatitis therapeutics market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including hepatitis A, hepatitis B and hepatitis C.
- Analysis of the hepatitis therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global hepatitis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to :
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC035MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents45
1.1 List of Tables61
1.2 List of Figures72
2 Global Hepatitis Therapeutics Market: Introduction 92
2.1 GBI Research Report Guidance101
3 Global Hepatitis Therapeutics Market: Market Overview1111
3.1 Introduction111
Revenue Forecasts for the Global Hepatitis Therapeutics Market121
3.2.1 Sales Value121
Annual Cost of Therapy131
3.2.2 Treatment Usage Patterns141
3.2.2.1 Diseased Population152
Treatment Seeking Population171
3.2.2.2 Diagnosed Population181
3.2.2.3 Prescription Population191
3.3 Hepatitis Market Drivers191
3.3.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline 191
3.3.2 Promising Developments in Hepatitis C Pipeline 191
3.3.3 Steady Increase in Prescription Population 201
3.4 Hepatitis Market Restraints201
3.4.1 Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms during Acute Phase 201
3.4.2 Low Treatment Seeking Population 201
3.4.3 Loss of Exclusivity Protection in Hepatitis B Market201
3.5 Generic Share in the Global Hepatitis Market211
4 Global Hepatitis Market: Therapeutic Landscape2223
4.1 Introduction221
4.1.1 Hepatitis A221
4.1.2 Hepatitis B221
4.2 Overview of Hepatitis A and B Vaccines Market231
4.2.1 Sales Value231
4.3 Hepatitis B Market241
4.3.1 Introduction241
4.3.2 Sales Value251
4.3.3 Annual Cost of Therapy261
4.3.4 Treatment Usage Patterns271
4.3.4.1 Diseased Population281
4.3.4.2 Treatment Seeking Population291
4.3.4.3 Diagnosed Population301
4.3.4.4 Prescription Population311
4.3.5 Geographical Segmentation322
4.4 Hepatitis C Market341
4.4.1 Introduction341
4.4.2 Sales Value351
Annual Cost of Therapy361
4.4.4 Treatment Usage Patterns371
4.4.4.1 Diseased Population381
4.4.4.2 Treatment Seeking Population391
4.4.4.3 Diagnosed Population401
4.4.4.4 Prescription Population 411
4.4.5 Geographical Segmentation423
5 Global Hepatitis Market: Geographical Landscape4524
5.1 Geographical Break-up453
5.2 The US481
5.2.1 Sales Value481
5.2.2 Annual Cost of Therapy491
5.2.3 Treatment Usage Patterns501
5.2.3.1 Diseased Population511
5.2.3.2 Treatment Seeking Population521
5.2.3.3 Diagnosed Population531
5.2.3.4 Prescription Population 541
5.3 Top Five Countries in Europe551
5.3.1 Sales Value551
5.3.2 Annual Cost of Therapy561
5.3.3 Treatment Usage Patterns571
5.3.3.1 Diseased Population581
5.3.3.2 Treatment Seeking Population591
5.3.3.3 Diagnosed Population601
5.3.3.4 Prescription Population 611
5.4 Japan621
5.4.1 Sales Value621
5.4.2 Annual Cost of Therapy631
5.4.3 Treatment Usage Patterns641
5.4.3.1 Diseased Population651
5.4.3.2 Treatment Seeking Population661
5.4.3.3 Diagnosed Population671
5.4.3.4 Prescription Population 681
6 Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis6912
6.1 Introduction692
6.1.1 Research and Development Pipeline Hepatitis B Therapeutics711
6.1.2 Research and Development Pipeline Hepatitis C Therapeutics721
6.2 Profiles of Key Late-Stage Vaccines in the Hepatitis A &B Market731
6.2.1 Heplisav731
6.2.1.1 Introduction731
6.2.1.2 Mechanism of Action731
6.2.1.3 Clinical Trial Management731
6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development 741
6.3.1 Entecavir + Adefovir combination therapy741
6.3.1.1 Introduction741
6.3.1.2 Mechanism of Action741
6.3.1.3 Clinical Trial Management741
6.3.2 Truvada (Tenofovir plus Emtricitabine combination therapy)741
6.3.2.1 Introduction741
6.3.2.2 Mechanism of Action741
6.3.2.3 Clinical Trial Management751
6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development 751
6.4.1 Boceprevir (SCH 503034, narlaprevir)751
6.4.1.1 Introduction751
6.4.1.2 Mechanism of Action751
6.4.1.3 Clinical Trial Management751
6.4.2 Tenofovir + Emtricitabine Combination therapy761
6.4.2.1 Introduction761
6.4.2.2 Clinical Trial Management761
6.4.3 Zalbin (albinterferon alfa-2b, Joulferon)761
6.4.3.1 Introduction761
6.4.3.2 Mechanism of Action761
6.4.3.3 Clinical Trial Management771
6.4.4 Telaprevir (VX 905)771
6.4.4.1 Introduction771
6.4.4.2 Mechanism of Action771
6.4.4.3 Clinical Trial Management781
6.4.5 RG 7128791
6.4.5.1 Introduction791
6.4.5.2 Mechanism of Action791
6.4.5.3 Clinical Trial Management792
Global Hepatitis Vaccines &Therapeutics Market: Competitive Landscape818
7.1 Market Share Analysis: Hepatitis811
7.2 Competitive Profiling821
7.2.1 Merck &Co., Inc.821
7.2.1.1 SWOT Analysis831
7.2.1.2 Product Portfolio841
7.2.2 F. Hoffmann-La Roche Ltd.851
7.2.2.1 SWOT Analysis851
7.2.2.2 Product Portfolio861
7.2.3 GlaxoSmithKline plc871
7.2.3.1 SWOT Analysis871
7.2.3.2 Product Portfolio881
8 Global Hepatitis Market: Strategic Consolidations897
8.1 Mergers and Acquisitions891
8.1.1 Overview891
8.1.1.1 Deals by Geography 891
8.1.1.2 Deals by Type901
8.1.2 Summary of M&A Deals (2009-2010)901
8.1.2.1 China Life Insurance to Acquire Sino Biopharmaceutical901
8.1.2.2 Diasorin to Acquire MUREX Product Line From Abbott Laboratories901
8.1.2.3 Nova Laboratories Acquires Cambridge Biostability901
8.1.2.4 LTT Bio-Pharma Completes the Sale of 19.2% Stake in the Company901
8.1.2.5 Calzada Acquires Minority Stake in Avexa911
8.2 R&D Licensing Agreements911
8.2.1 Summary of Licensing Deals (2009-2010)911
8.2.1.1 Medivir Enters Into Licensing Agreement With Daewoong Pharmaceutical911
8.2.1.2 Debiopharm Enters Into Licensing Agreement With Novartis911
8.2.1.3 Achillion Pharmaceuticals Enters Into Licensing Agreement With GCA Therapeutics921
8.2.1.4 Advanced Biological Laboratories Enters Into Licensing Agreement With CRP-Sante921
8.2.1.5 Bristol-Myers Squibb Enters Into An Agreement With ZymoGenetics921
8.2.1.6 Cyplasin Biomedical Enters Into Licensing Agreement With Virionics921
8.2.1.7 GlaxoSmithKline Enters Into Licensing Agreement With Gilead Sciences931
8.2.1.8 Stanford University Enters Into Worldwide Licensing Agreement With Eiger BioPharmaceuticals931
8.2.1.9 Vertex Pharmaceuticals Amends Agreement With Mitsubishi Tanabe Pharma931
8.2.1.10 Valeant Pharmaceuticals Enters Into Option Licening Agreement With Schering-Plough931
8.2.1.11 ViroStatics Enters Into Licensing Agreement With University of Siena931
8.2.1.12 Chugai Pharmaceutical Signs Licensing Agreement With Romark Laboratories941
8.2.1.13 Virco Enters Into Licensing Agreement With Siemens Healthcare Diagnostics941
8.2.1.14 Evivar Medical Enters Into Licensing Agreement With Advanced Biological Laboratories941
8.2.1.15 Biotecnol And Digna Biotech Enters Into Licensing Agreement With Genentech941
8.2.1.16 Hadasit Enters Into Licensing Agreement With Immuron951
9 Global Hepatitis Market: Appendix966
9.1 Market Definitions961
9.2 Abbreviations961
9.3 Research Methodology971
9.4 Research Methodology974
9.4.1 Coverage 971
9.4.2 Secondary Research971
9.4.3 Primary Research981
9.4.4 Forecasts981
9.4.4.1 Epidemiology-based Forecasting982
9.4.5 Expert Panel Validation1001
9.5 Contact Us1011
9.6 Disclaimer1011

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market" Sep 30, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Hepatitis-Therapeutics-Market-to-2016-Strong-Hepatitis-C-Pipeline-and-Cost-Effective-Treatments-will-Drive-the-Global-Hepatitis-Market-2115-92>
  
APA:
GBI Research Reports. (2010). Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market Sep 30, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Hepatitis-Therapeutics-Market-to-2016-Strong-Hepatitis-C-Pipeline-and-Cost-Effective-Treatments-will-Drive-the-Global-Hepatitis-Market-2115-92>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.